Ginkgo Bioworks Stock News

BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks announced a series of new initiatives to accelerate the application of artificial intelligence in biologics drug discovery.

BOSTON , Aug. 29, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today released the following notice: UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA OAKLAND DIVISION WEINING HU, derivatively on behalf of GINKGO BIOWORKS HOLDINGS, INC., a Delaware corporation,                                                           Plaintiff,                                      vs.

BOSTON , Aug. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entered into a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven lab-in-the-loop drug discovery broadly accessible across the industry. The partnership aims to delive...

Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs. BOSTON , Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointmen...

Ginkgo Bioworks' shares have rallied tremendously, and Q2 results showed a headline revenue beat with no upward guidance revision. Biosecurity segment guidance was cut, and overall revenue estimates have plunged, raising concerns about future growth. Despite cost reductions, Ginkgo continues to post large operating losses and faces ongoing cash burn, prompting a $500 million shelf offering.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q2 2025 Earnings Conference Call August 7, 2025 5:30 PM ET Company Participants Daniel Waid Marshall - Senior Manager of Communications and Ownership Jason Kelly - Founder, CEO & Director Steven P. Coen - Chief Accounting Officer & CFO Daniel Waid Marshall Good evening.

Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON , Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slid...

Presentation and Q&A session scheduled for post-market on Thursday, August 7, 2025 BOSTON , July 31, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2025, ...